Impact of erythropoietin on intensive care unit patients

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 5, 2013, Pages 310-318

  Jelkmann, Ines ^a   Jelkmann, Wolfgang ^b  

^a Department of Surgery ^*  (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anemia; Blood transfusion; Critical care unit; Hypoxia; Intensive care unit; Recombinant human erythropoietin; Red blood cells

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; FERROPORTIN 1; GAMMA INTERFERON; HEMOGLOBIN; HEPARIN; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON SACCHARATE; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROTOPORPHYRIN ZINC; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TUMOR NECROSIS FACTOR; ZIDOVUDINE;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ANEMIA; APOPTOSIS; BLOOD TRANSFUSION; BRAIN INJURY; BRAIN ISCHEMIA; BURN; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT E; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; ERYTHROCYTE TRANSFUSION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; IRON DEFICIENCY; JEHOVAH'S WITNESS; MORTALITY; MULTIPLE TRAUMA; MYELODYSPLASTIC SYNDROME; NEUROPROTECTION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROPHYLAXIS; PURE RED CELL ANEMIA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; RETICULOCYTE; RETICULOCYTE COUNT; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS; ERYTHROCYTE; ERYTHROPOIESIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; INFLAMMATION; MEDIATOR; META ANALYSIS; MYOCARDIAL DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; RELIGION; TRAUMATIC BRAIN INJURY;

EID: 84886609290     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000354128     Document Type: Review

References (92)

1. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D: Anemia and blood transfusion in critically ill patients. JAMA 2002;288: 1499-1507.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ: The CRIT Study: anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004;32: 39-52.
3. Vamvakas EC, Blajchman MA: Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113: 3406-3417.
4. Marik PE, Corwin HL: Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008;36: 2667-2674.
5. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Tisherman SA, Hebert PC, Anderson GL, Bard MR, Bromberg W, Chiu WC, Cipolle MD, Clancy KD, Diebel L, Hoff WS, Hughes KM, Munshi I, Nayduch D, Sandhu R, Yelon JA: Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009; 37: 3124-3157.
6. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG: 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91: 944-982.
7. Stubbs JR: Alternatives to blood product transfusion in the critically ill: erythropoietin. Crit Care Med 2006;34(5 suppl):S160-S169.
8. Corwin HL: The role of erythropoietin therapy in the critically ill. Transfus Med Rev 2006;20: 27-33.
9. Afshar M, Netzer G: Update in critical care for the nephrologist: transfusion in nonhemorrhaging critically ill patients. Adv Chronic Kidney Dis 2013;20: 30-38.
10. Jelkmann W: Physiology and pharmacology of erythropoietin. Transfus Med Hemother 2013;40: 302-309.
11. Aher SM, Ohlsson A: Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012;10:CD004865.
12. World Health Organisation: Nutritional anaemias. Report of a WHO scientific group; World Health Organ Tech Rep Ser, 1968, pp 5-37.
13. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B: Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009;12: 444-454.
14. Singh S, Gudzenko V, Fink MP: Pathophysiology of perioperative anaemia. Best Pract Res Clin Anaesthesiol 2012;26: 431-439.
15. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU: Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999;27: 2630-2639.
16. Hayden SJ, Albert TJ, Watkins TR, Swenson ER: Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med 2012;185: 1049-1057.
17. Robinson Y, Hostmann A, Matenov A, Ertel W, Oberholzer A: Erythropoiesis in multiply injured patients. J Trauma 2006;61: 1285-1291.
18. Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18: 555-559.
19. Rogiers P, Zhang H, Leeman M, Nagler J, Neels H, Melot C, Vincent JL: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997;23: 159-162.
20. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28: 2773-2778.
21. Hobisch-Hagen P, Wiedermann F, Mayr A, Fries D, Jelkmann W, Fuchs D, Hasibeder W, Mutz N, Klingler A, Schobersberger W: Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med 2001;29: 743-747.
22. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC: Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003;14: 1776-1784.
23. Abel J, Spannbrucker N, Fandrey J, Jelkmann W: Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996;57: 359-363.
24. Finberg KE: Regulation of systemic iron homeostasis. Curr Opin Hematol 2013;20: 208-214.
25. Ganz T, Nemeth E: Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62: 347-360.
26. Walsh TS, Saleh EE: Anaemia during critical illness. Br J Anaesth 2006;97: 278-291.
27. Wolff M, Fandrey J, Hirner A, Jelkmann W: Perioperative use of recombinant human erythropoietin in patients refusing blood transfusions. Pathophysiological considerations based on 5 cases. Eur J Haematol 1997;58: 154-159.
28. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340: 409-417.
29. Hebert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, Tweeddale M, Pagliarello G, Schweitzer I: Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29: 227-234.
30. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J: Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365: 2453-2462.
31. Sakr Y, Lobo S, Knuepfer S, Esser E, Bauer M, Settmacher U, Barz D, Reinhart K: Anemia and blood transfusion in a surgical intensive care unit. Crit Care 2010;14:R92.
32. Lelubre C, Vincent JL: Red blood cell transfusion in the critically ill patient. Ann Intensive Care 2011;1: 43.
33. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292: 1555-1562.
34. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H: Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J 2007;28: 1289-1296.
35. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E: Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111: 2042-2049.
36. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED: The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005;46: 1490-1495.
37. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT: Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007;116: 471-479.
38. Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK: Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol 2004;44: 541-546.
39. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM: Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230-1236.
40. Hebert PC, Fergusson DA: Do transfusions get to the heart of the matter? JAMA 2004;292: 1610-1612.
41. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345: 1368-1377.
42. Sweet D, Marsden J, Ho K, Krause C, Russell JA: Emergency management of sepsis: the simple stuff saves lives. BC Med J 2012;54: 176-182.
43. Mazza BF, Machado FR, Mazza DD, Hassmann V: Evaluation of blood transfusion effects on mixed venous oxygen saturation and lactate levels in patients with SIRS/sepsis. Clinics (Sao Paulo) 2005; 60: 311-316.
44. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B: Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;157: 49-58.
45. Retter A, Wyncoll D, Pearse R, Carson D, Mc- Kechnie S, Stanworth S, Allard S, Thomas D, Walsh T: Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013;160: 445-464.
46. Jelkmann W: Regulation of erythropoietin production. J Physiol 2011;589: 1251-1258.
47. Major A, Mathez-Loic F, Rohling R, Gautschi K, Brugnara C: The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997;98: 292-294.
48. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of endstage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316: 73-78.
49. Naidech AM, Kahn MJ, Soong W, Green D, Batjer HH, Bleck TP: Packed red blood cell transfusion causes greater hemoglobin rise at a lower starting hemoglobin in patients with subarachnoid hemorrhage. Neurocrit Care 2008;9: 198-203.
50. Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N: The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67: 2346- 2353.
51. Macdougall IC, Roger SD, De Francisco A, Goldsmith D, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Horl WH, Kemeny M, Pollock C: Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis stimulating agents: new insights. Kidney Int 2012;81: 727-732.
52. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y: Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 2011;126: 114-118.
53. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ: Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, doubleblind, placebo-controlled trial. Crit Care Med 1999; 27: 2346-2350.
54. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T: Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288: 2827-2835.
55. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357: 965-976.
56. Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS: Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Crit Care Med 2006;34: 1661-1667.
57. Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A: Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 2005;9:R508-R515.
58. KDIGO: KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012;2: 272-335.
59. Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG: High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998;44: 361-367.
60. Arroliga AC, Guntupalli KK, Beaver JS, Langholff W, Marino K, Kelly K: Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med 2009;37: 1299-1307.
61. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA: Erythropoietin- receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007;177: 725-734.
62. Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL: Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma 2008;65: 285-297.
63. Hare GM, Tsui AK, McLaren AT, Ragoonanan TE, Yu J, Mazer CD: Anemia and cerebral outcomes: many questions, fewer answers. Anesth Analg 2008;107: 1356-1370.
64. Talving P, Lustenberger T, Kobayashi L, Inaba K, Barmparas G, Schnuriger B, Lam L, Chan LS, Demetriades D: Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010;251: 1-4.
65. Luchette FA, Pasquale MD, Fabian TC, Langholff WK, Wolfson M: A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study. Am J Surg 2012; 203: 508-516.
66. Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL: Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double- blind, placebo-controlled trial. Crit Care Med 2006;34: 2310-2316.
67. Chui BK, Pannu N, Hazel M, Dong J, Tonelli M, Klarenbach SW: Economic analysis of epoetin alfa in critically ill trauma patients. J Trauma Acute Care Surg 2012;73: 195-201.
68. Jelkmann W, Elliott S: Erythropoietin and the vascular wall: the controversy continues. Nutr Metabol Cardiovasc Dis Nutr Metab Cardiovasc Dis 2012; doi: 10.1016/j.numecd.2012.04.002.
69. Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E, Venugopal V, Walker M, Holdright D, Swanton H, Crake T, Brull D, Moon JC, Puranik R, Mutharangu V, Taylor A, Hausenloy DJ: Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011;97: 1560-1565.
70. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A: Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3: 408-413.
71. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ; HEBE III Investigators: A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31: 2593-2600.
72. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA: Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305: 1863-1872.
73. Li J, Xu H, Gao Q, Wen Y: Effect of erythropoiesis- stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Eur J Clin Pharmacol 2011;68: 469-477.
74. Gao D, Ning N, Niu X, Dang Y, Dong X, Wei J, Zhu C: Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J 2012;164: 715-727.
75. Grmec S, Strnad M, Kupnik D, Sinkovic A, Gazmuri RJ: Erythropoietin facilitates the return of spontaneous circulation and survival in victims of out-of-hospital cardiac arrest. Resuscitation 2009; 80: 631-637.
76. Kramer AH, Zygun DA: Anemia and red blood cell transfusion in neurocritical care. Crit Care 2009;13:R89.
77. Siren AL, Fasshauer T, Bartels C, Ehrenreich H: Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009;6: 108-127.
78. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth M, Bahr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C: Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40: 647-656.
79. Ehrenreich H, Kastner A, Weissenborn K, Streeter J, Sperling S, Wang KK, Worthmann H, Hayes RL, von AN, Kastrup A, Jeromin A, Herrmann M: Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med 2011;17: 1306-1310.
80. Robertson C, Sadrameli S: Erythropoietin in the neurology ICU. Curr Treat Options Neurol 2013; 15: 104-112.
81. Patel NS, Nandra KK, Thiemermann C: Bench-tobedside review: erythropoietin and its derivatives as therapies in critical care. Crit Care 2012;16: 229.
82. Still JM Jr, Belcher K, Law EJ, Thompson W, Jordan M, Lewis M, Saffle J, Hunt J, Purdue GF, Waymack JP, et al: A double-blinded prospective evaluation of recombinant human erythropoietin in acutely burned patients. J Trauma 1995;38: 233-236.
83. Lundy JB, Hetz K, Chung KK, Renz EM, White CE, King BT, Huzar T, Wolf SE, Blackbourne LH: Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. Am Surg 2010;76: 951-956.
84. Gunter CI, Bader A, Dornseifer U, Egert S, Sebastian D, Grieb G, Wolter T, Pallua N, von WT, Siemers F, Mailander P, Thamm O, Ernert C, Steen M, Sievers R, Reichert B, Rahmanian-Schwarz A, Schaller H, Hartmann B, Otte M, Kehl V, Ohmann C, Jelkmann W, Machens HG: A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial. Trials 2013;14: 124.
85. Dumont F, Bischoff P: Non-erythropoietic tissueprotective peptides derived from erythropoietin: WO2009094172. Expert Opin Ther Pat 2010;20: 715-723.
86. Elliott S, Sinclair A.: The effect of erythropoietin on normal and neoplastic cells. Biologics 2012;6: 163-189.
87. Solling C: Organ-protective and immunomodulatory effects of erythropoietin - an update on recent clinical trials. Basic Clin Pharmacol Toxicol 2011; 110: 113-121.
88. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY: Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30: 253-260.
89. de Seigneux S., Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P: Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012;13: 132.
90. Haljan G, Maitland A, Buchan A, Arora RC, King M, Haigh J, Culleton B, Faris P, Zygun D: The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009;40: 2769-2775.
91. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM: Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010;77: 1020-1030.
92. Ball AM, Winstead PS: Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy 2008;28: 1383-1390.